Literature DB >> 34474044

Men Converting from Clomiphene Citrate to Natesto with a Desire to Maintain Spermatogenesis Should Be Followed Closely.

Parviz K Kavoussi1.   

Abstract

OBJECTIVE: To report a case of a testosterone deficient man desiring maintenance of spermatogenesis converting from clomiphene citrate (CC) to Natesto, who had a decrease in gonadotropins and semen parameter values after making this medication change. The data on men maintaining gonadotropins and semen parameter values after converting from CC to Natesto is also reported.
METHODS: A retrospective chart review was performed. Baseline hormones prior to treatment, and again on CC and Natesto, as well as semen parameters on CC and on Natesto were assessed.
RESULTS: A 32-year-old testosterone deficient man desiring to maintain future fertility potential who had a poor symptomatic response to CC despite an adequate serum testosterone response was converted to Natesto 11 mg twice daily. His gonadotropins diminished as did his semen parameter values but with dose titration of Natesto to 11 mg in the morning and 5.5 mg in the evening he had normalization of gonadotropins and a rise in semen parameter values back towards his values on CC with a continued satisfactory symptomatic response. The remainder of the 49 men to date converting from CC to Natesto revealed stability in gonadotropins and semen parameter values.
CONCLUSION: Testosterone deficient men interested in maintaining spermatogenesis who convert from CC to Natesto seeking a more robust symptomatic response should be followed closely with repeat serum gonadotropins and semen parameters to confirm that spermatogenesis is not being suppressed. Dose titration of Natesto may be effective at optimizing gonadotropins, semen parameter values, testosterone levels, and symptomatic response to treatment.
Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34474044     DOI: 10.1016/j.urology.2021.08.028

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.633


  1 in total

1.  Direct conversion from long-acting testosterone replacement therapy to Natesto allows for spermatogenesis resumption: Proof of concept.

Authors:  Parviz K Kavoussi; Graham L Machen; Shu-Hung Chen; Melissa S Gilkey; Justin Chen; Yazan Hamzeh; Kenneth I Aston; Shahryar K Kavoussi
Journal:  Andrologia       Date:  2022-05-06       Impact factor: 2.532

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.